COMPANY PROFILE

Anaconda BioMed

Explore full profile

Developing the next generation of catheters to perform safely and efficiently mechanical thrombectomies

Sant Cugat del Vallès, SpainFounded 2015Health Tech & Medtech

Valuation $100–250M Last recorded · 2025

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Anaconda BioMed

Anaconda Biomed S.L., based in Barcelona, is a pioneering medical device startup co-founded by Dr. Marc Ribo and Dr. Ofir Arad. The company specializes in developing advanced catheters designed to perform mechanical thrombectomies safely and efficiently. Mechanical thrombectomy is a procedure used to remove blood clots from arteries in the brain, which is crucial in treating strokes. Strokes are the leading cause of permanent disability globally, imposing a significant financial burden on national health systems, amounting to billions of dollars annually.

Read full description

Anaconda Biomed's core product, the ANCD Advanced Thrombectomy System, combines innovative techniques such as the Stentriever and Aspiration methods. This system aims to minimize risks associated with traditional methods, such as distal emboli and clot fragmentation, by using a covered funnel and clot mobilizer. The company has demonstrated the efficacy of its technology through in vivo studies, with findings published in the Journal of Neurointerventional Surgery in December 2019.

The primary market for Anaconda Biomed's products includes hospitals and medical institutions specializing in stroke treatment. The business model revolves around the development, manufacturing, and sale of these specialized catheters. Revenue is generated through direct sales to healthcare providers and potential partnerships with medical device distributors.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Sant Cugat del Vallès, Spain
Employees: 44
Open positions: None listed
Dealroom signal: 80.7/100
Industry: Health
Sub-industry: Medical Devices
Sector: Health Tech & Medtech, Cardiology and cardiovascular, Catheters, Intravenous, Spinout, Hospital, Headstart (EIT Health), Headstart 2018 (EIT Health), EIT Health
Technology: Hardware, Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jan 2025	$3.7M	$111M	CDTI · Asabys Partners · Ysios Capital	↗
DEBT✓Debt	Oct 2021	$11M	—	European Investment Bank	—

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Anaconda BioMed website traffic

Latest recorded traffic for Anaconda BioMed is 1.9K monthly website visits, up 35.7% over the last three months. Anaconda BioMed's team grew 2.3% over the past year.

Latest monthly visits1.9K 3-month web change+35.7% 1-year team growth+2.3%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Clinical Specialist – U.S. Field ClinicalSant Cugat del Vallès, Barcelona, Spain · Other · Aug 23, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IMInVera MedicalDeveloping the world's first pain-free and effective medical device treatment for all chronic venous disease sufferers	Galway, Ireland	Operational	11	$7.8M	$21M
STSTENTiTMedical device company that focuses on the development of regenerative endovascular implants	Eindhoven, Netherlands	Operational
CTCavis TechnologiesInnovative start-up company supplying diagnostic tools with unique precision within the coronary field	Uppsala kommun, Sweden	Operational
CRCroivalveTreating Heart Valve Disease	Dublin, Ireland	Operational
IAInterlinked ABReLink features a self-sealable, double-valve system that reduces spillage in the event of a accidental catheter dislodgement	Stockholms kommun, Sweden	Operational
GDGlyCardial DiagnosticsSpin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia	Barcelona, Spain	Operational
FBFreeOx BiotechAdvancing Stroke Care through Innovation and Precision Medicine	Barcelona, Spain	Operational
SISideROSFocused on accelerated development of innovative small molecules targeting tumour cells metabolism in high-risk cancers	Paris, France	Closed